Expected to grow at a CAGR of 15.2%, the global Genomics in Cancer Care Market is USD 28.7 billion in 2022 and USD 93.5 billion by 2031. North America is expected to take front stage in the market during the complete project time.
Fast growth of the Genomics in Cancer Care Market is driven by developments in genetic technology, rising cancer incidence, and increased demand for individualized medicine. From the revolution in diagnosis, treatment choice, and monitoring made possible by the integration of genes in cancer care, improved patient outcomes and reduced healthcare costs follow. Supported government initiatives in line with increased financing for research and development assist to propel market expansion even further.
Market Trend: Integration of Artificial Intelligence and Machine Learning in Genetic Data Analysis
Integration of artificial intelligence (AI) and machine learning techniques in genetic data processing is changing cancer therapy. By virtue of their impact on these aspects, faster and more accurate interpretation of complex genetic data made available by modern technology is helping to improve diagnosis, treatment choice, and patient outcomes. Artificial intelligence-powered tools might be able to detect connections and patterns in enormous amounts of genomic data that would be difficult for human researchers to uncover. From this paradigm, more sophisticated genetic testing tools and decision support systems for oncologists are evolving. New biomarkers and probable treatment targets let artificial intelligence advance medicine development and cancer research as well. These technologies are expected to be even more crucial in customized cancer treatment plans as they let the genomes in the cancer care sector grow and help each other.
Market Driver: Growing market increasing need for customized medications to cure cancer
The growing need for tailored medicine in cancer treatment mostly drives the genetics available for cancer treatment on the market. Using a person's genetic profile, personalized or precision medicine alters treatment approaches, therefore improving efficacy and reducing side effects. Genomic testing guides the choice of more likely effective customized therapies by letting doctors identify specific genetic changes underlying a patient's cancer. This approach not only enhances the outcomes of therapy but also helps to cut unnecessary treatments, therefore reducing healthcare costs and raising patient quality of life. The success of customized treatment in many cancer types has improved patient knowledge and drawn increasing respect among experts in the area. Pharmaceutical companies significantly investing in tailored drugs dependent on genetic indicators will help even more market development. As more genetically based treatments become available and clinical evidence demonstrating their efficacy accumulates, the need for genetic testing and analysis in cancer therapy is expected to expand and drive major market growth.
Restrain of the Market: Testing and analyzing genes is expensive.
The enormous costs of genetic testing and analysis drastically restrict the spread of the genomics in the area of cancer therapy. While the cost of sequencing technology has decreased over time, complete genetic profiling is still expensive and hence not readily accessible to many individuals. Apart from the sequencing itself, the costs include the complex data processing, interpretation, and storage of massive volumes of genetic data. Many insurance companies and healthcare systems have also not yet fully combined coverage for these tests, which increases out-of-pocket expenses. In low- and middle-income countries, when healthcare resources are sparse, the financial strain might be somewhat heavy. Furthermore, the whole cost depends on the demand of highly educated experts and certain instruments to execute and evaluate genetic research. These financial restrictions might influence public acceptability of genetic testing in cancer therapy, thereby slowing down firm growth. Realizing the complete potential of genomics in cancer therapy hinges on overcoming cost-related issues by means of technology advances, economies of scale, and advantageous reimbursement regulations.
The portion on technology discovers rules on next-generation sequencing.
Next-Generation Sequencing (NGS) technology is rising as the major participant in the genomics for cancer therapy market. Comprehensive genomic profiling of malignancies is made possible in part by rapid, reasonably cost sequencing technologies offered by NGS. This method concurrently analyzes many genes and different genomic modifications including mutations, copy number variations, and structural rearrangements. NGS has changed cancer diagnosis, treatment approach, and surveillance by fully comprehending the genetic topography of individual cancers. Driven by its potential to do whole genome, exome, and targeted panel sequencing, NGS has proven to be a vital tool in personalized cancer therapy and is therefore quite often employed in clinical oncology and research settings.
Regarding cancer treatment, North America is top globally.
North America leads the globe in cancer treatment because of first-rate healthcare infrastructure and great acceptance of new technologies. The area advances with major investments in genomics research, the existence of major market actors, and a regulatory environment supporting field leadership. Particularly the United States has been leading in adding genes into cancer therapy using programs like Precision Medicine Initiative and Cancer Moonshot accelerating progress. High healthcare expenses, broad understanding of tailored treatment, and a large patient base help to fuel market growth in some measure. Moreover supporting North America's dominance as the primary market for genomics in cancer therapy are top cancer research facilities and a robust biotechnology sector, thereby encouraging innovation and fast translation of genomic discoveries into clinical practice.
The area of cancer treatment has strong competitiveness and quick technological development that defines its genetics. Concentrated on developing novel genetic testing platforms, expanding their test ranges, and enhancing data analysis capabilities, are important firms To optimize complementing capabilities and accelerate market development, strategic alliances involving genomics firms, pharmaceutical companies, and healthcare providers are multiplying. Many companies are currently funding artificial intelligence and machine learning in order to improve the accuracy and efficiency of genetic data interpretation. Larger companies buying smaller, specialist companies to boost their technical ability and market presence reflect industry consolidation. As the sector grows, increasing industrial competition is expected to stimulate more innovation and maybe provide readily accessible and fairly priced genetic solutions for cancer therapy.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories, Inc.
- Exact Sciences Corporation
- Caris Life Sciences
- Foundation Medicine, Inc.
- Natera, Inc.
- Personal Genome Diagnostics Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Genomics in Cancer Care Market (2018 – 2022)
3.2. Global Genomics in Cancer Care Market (2023 – 2031)
3.2.1. Market Segment By Technology (2023 – 2031)
3.2.2. Market Segment By Application (2023 – 2031)
3.2.3. Market Segment By End User (2023 – 2031)
3.2.4. Market Segment By Region (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Integration of AI and machine learning in genomic data analysis
4.1.2. Liquid biopsy and circulating tumor DNA analysis
4.1.3. Integration of multi-omics approaches
4.2. Market Drivers
4.2.1. Rising demand for personalized medicine in cancer treatment
4.2.2. Advancements in sequencing technologies
4.2.3. Increasing cancer prevalence globally
4.3. Market Restraints
4.3.1. High costs associated with genomic testing and analysis
4.3.2. Data interpretation and storage challenges
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TECHNOLOGY (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Next-Generation Sequencing
5.2. Polymerase Chain Reaction
5.3. Microarray
5.4. Sanger Sequencing
6. BY APPLICATION
6.1. Diagnostics
6.2. Personalized Medicine
6.3. Drug Discovery & Development
7. BY END USER
7.1. Hospitals & Clinics
7.2. Research Institutes
7.3. Pharmaceutical & Biotechnology Companies
8. GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. Illumina, Inc.
11.2. Thermo Fisher Scientific Inc.
11.3. QIAGEN N.V.
11.4. F. Hoffmann-La Roche Ltd
11.5. Agilent Technologies, Inc.
11.6. Myriad Genetics, Inc.
11.7. NeoGenomics Laboratories, Inc.
11.8. Exact Sciences Corporation
11.9. Caris Life Sciences
11.10. Foundation Medicine, Inc.
11.11. Natera, Inc.
11.12. Personal Genome Diagnostics Inc.
12. MARKET OPPORTUNITIES
By Application:
By End User:
By Region:
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
